case_images: PMC3896700_01
case_images: hIL6, HHV8 and CRP dynamic. Changes in the levels of human interleukin-6 (hIL6), human herpesvirus 8 (HHV8) DNA and serum C-reactive protein (CRP) in Cases 1 and 2 following the initiation of tocilizumab therapy.   hIL6,  CRP and   HHV8 in the serum.   The arrows indicate the time of relapse. The gray boxes indicate the frequency of tocilizumab infusion.
case_images: 1756-8722-7-10-1.jpg
case_images: PMC3896700_02_1756-8722-7-10-1.jpg
case_images: F1
case_images: The levels of HHV8 and hIL6 decreased to 5,100 copies/mug and 35 pg/ml, respectively, eight weeks after treatment (Figure 1, Case 2).
case_images: PMC3896700_02
case_images: hIL6, HHV8 and CRP dynamic. Changes in the levels of human interleukin-6 (hIL6), human herpesvirus 8 (HHV8) DNA and serum C-reactive protein (CRP) in Cases 1 and 2 following the initiation of tocilizumab therapy.   hIL6,  CRP and   HHV8 in the serum.   The arrows indicate the time of relapse. The gray boxes indicate the frequency of tocilizumab infusion.
case_images: 1756-8722-7-10-1.jpg
case_images: PMC3896700_02_1756-8722-7-10-1.jpg
case_images: F1
case_images: The levels of HHV8 and hIL6 decreased to 5,100 copies/mug and 35 pg/ml, respectively, eight weeks after treatment (Figure 1, Case 2).